Adrenergic agonist apraclonidine

Gharagozloo NZ, Relf SJ, Brubaker RF. Aqueous flow is reduced by the alpha-adrenergic agonist apraclonidine hydrochloride (ALO 2145). Ophthalmology 1988 95 1217-1220. 

CY2-Adrenergic agonists Apraclonidine Specific a2-agonists lopidine Solution 0.5, 1 1 drop two to three times Both reduce aqueous humor... 

Pharmacology Apraclonidine hydrochloride is a relatively selective -adrenergic agonist. When instilled into the eyes, apraclonidine reduces intraocular pressure (lOP) and has minimal effect on cardiovascular parameters. 

Apraclonidine 1% 0.2 Adrenergic agonist Mydriatic Dilates Horner s pupil but fails to dilate normal pupil... 

Two a-adrenergic agonists are available on the market. Apraclonidine 0.5% is indicated when a patient on maximum tolerated medical therapy requires short-term additional lOP lowering. Before the introduction of brimonidine, apraclonidine was the only available a-adrenergic agonist and was FDA approved for short-term use. Approximately one-third of patients using apraclonidine showed little or no treatment effect. For another third the treatment effect (3 to 5 mm Hg) was short in duration (3 to 6 months) for the remainder the effect was more lasting. Consequently, this medication... 

Topical a-adrenergic agonist every 15 minutes (e.g., apraclonidine 0.5%), 1 drop... 

Brimonidine and the less lipid-soluble and less receptor-selective apraclonidine are 2-adrenergic agonists structurally similar to cloni-dine. Apraclonidine is indicated and brimonidine is effective for prevention or control of postoperative or postlaser treatment increases in lOP and both are indicated in the treatment of open-angle glaucoma. Brimonidine is considered a first-line or adjunctive agent in the therapy of POAG, and apraclonidine is seen as a second-line or adjunctive therapy. 

---